Table 2.

Comparative studies.

Author (Year)	Groups Studied and Intervention	Results and Findings	Conclusions
Cameron C. et al. (2017) [98]	A NMA, with searches from MED- LINE, Embase, Cochrane CENTRAL, PsycINFO, ClinicalTrials.gov, International Clinical Trials Registry Platform, and gray literature which identified four Phase III clinical trials (1 of AL and 3 of PP), for indirect comparison of AL and PP. Active-treatment groups were AL (441 mg and 882 mg monthly) and PP (156 mg and 234 mg monthly).	All four groups versus placebo resulted in substantial reduction in acute symptoms, as measured by the positive and negative syndrome scale; the range of mean difference was −8.12 to −12.01, with overlapping 95% credible intervals. No differences in efficacy, safety or tolerability were found between active-treatment groups.	AL and PP are equally efficacious in treating adults with acute exacerbation of schizophrenia.
Salzman P. et al. (2017) [99]	Aripiprazole steady-state plasma concentrations for two different LAI formulations, (aripiprazole once-monthly 400 mg [AOM 400] and AL), were compared. Cavg,ss for AOM 400 were obtained from a population Pk model, while those for AL were obtained from the Center for Drug Evaluation and Research (CDER). Cmin,ss for both LAIs were obtained from previously published clinical trials.	Cavg,ss values for AOM 400 and AL 882 mg given every 4 weeks were comparable, while AL 441 mg resulted in considerably lower Cavg,ss values. Cmin,ss values for the intragluteal injection of AOM 400 and the intragluteal injection of AL 882 mg every 4 weeks were also similar (200 ng/mL and 175 ng/mL, respectively).	Both AOM 400 mg and AL 882 mg administered every 4 weeks provided similar Aripiprazole steady-state plasma concentrations.